A recent study published in the Egyptian Journal of Radiology and Nuclear Medicine evaluates the implementation of single time-point (STP) dosimetry for calculating radiation doses in metastatic castration-resistant prostate cancer (mCRPC) patients treated with 177Lu-PSMA. Conducting SPECT/CT scans approximately 48 hours post-administration, researchers found the mean absorbed dose to the kidneys was 2.04 Gy, within safe limits, and the tumours received variable doses ranging from 0.98 to 16.05 Gy. This suggests that STP dosimetry combined with fast SPECT acquisition could enhance clinical practice by simplifying dosimetric processes, potentially improving patient care while minimizing the imaging burden. The efficiency of STP dosimetry may pave the way for broader applications of targeted radionuclide therapy in prostate cancer management.
Thu, 09 Oct 2025 09:21:08 GMT | SpringerOpen